IMARA(US:IMRA)2024-11-13 21:10Financial Performance - The net loss for Q3 2024 was $23.2 million, compared to a net loss of $20.8 million in Q3 2023[7]. - Enliven's total operating expenses for Q3 2024 were $27.1 million, up from $24.2 million in Q3 2023[7]. - Research and development (R&D) expenses for Q3 2024 were $21.3 million, an increase from $19.6 million in Q3 2023[7]. - General and administrative (G&A) expenses for Q3 2024 were $5.8 million, compared to $4.6 million in Q3 2023[7]. - The weighted-average shares outstanding for Q3 2024 were 48.3 million, compared to 41.0 million in Q3 2023[7]. Cash Position - The company has a strong cash position with $291.8 million in cash, cash equivalents, and marketable securities, expected to provide a cash runway into late 2026[7]. - Enliven's total assets as of September 30, 2024, were $305.4 million, an increase from $271.9 million as of December 31, 2023[7]. Clinical Trials and Research - Enliven Therapeutics reported a cumulative major molecular response (MMR) rate of 44.4% (8/18) for ELVN-001 in a Phase 1 clinical trial for chronic myeloid leukemia (CML) by 24 weeks[3]. - Enliven plans to report additional Phase 1 data for ELVN-001 in 2025, including approximately 60-100 patients across various lines of therapy[7]. - The company is progressing with ELVN-002, focusing on combination clinical trials for HER2+ metastatic breast cancer (MBC) and colorectal cancer (CRC)[3].